Franklin Resources
HRTX icon

Franklin Resources’s Heron Therapeutics HRTX Stock Holding History

Franklin Resources’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-77,552
Closed -$171K – 3075
2025
Q1 		$171K Buy
77,552
+54,526
+237% +$106K ﹤0.01% 2730
2024
Q4 		$35.2K Hold
23,026
– – ﹤0.01% 2827
2024
Q3 		$41.2K Sell
23,026
-6,304,716
-100% -$15.1M ﹤0.01% 2813
2024
Q2 		$22.1M Sell
6,327,742
-46,842
-0.7% -$144K 0.01% 824
2024
Q1 		$17.7M Sell
6,374,584
-30,211
-0.5% -$75.9K 0.01% 905
2023
Q4 		$10.9M Sell
6,404,795
-553,315
-8% -$609K 0.01% 909
2023
Q3 		$7.17M Sell
6,958,110
-499,942
-7% -$712K ﹤0.01% 980
2023
Q2 		$8.65M Sell
7,458,052
-4,412,044
-37% -$7.87M ﹤0.01% 956
2023
Q1 		$17.9M Buy
11,870,096
+2,316
+0% +$5.8K 0.01% 799
2022
Q4 		$29.7M Sell
11,867,780
-15,398
-0.1% -$49.6K 0.02% 672
2022
Q3 		$50.1M Buy
11,883,178
+51,654
+0.4% +$202K 0.03% 520
2022
Q2 		$33M Sell
11,831,524
-47,052
-0.4% -$189K 0.02% 665
2022
Q1 		$67.9M Sell
11,878,576
-88,889
-0.7% -$650K 0.03% 517
2021
Q4 		$109M Sell
11,967,465
-12,997
-0.1% -$133K 0.04% 445
2021
Q3 		$128M Sell
11,980,462
-1,288,258
-10% -$15.7M 0.05% 404
2021
Q2 		$206M Buy
13,268,720
+619,826
+5% +$9.86M 0.08% 284
2021
Q1 		$205M Sell
12,648,894
-39,808
-0.3% -$710K 0.08% 265
2020
Q4 		$269M Sell
12,688,702
-195,662
-2% -$3.4M 0.11% 215
2020
Q3 		$191M Buy
12,884,364
+319,056
+3% +$4.98M 0.09% 245
2020
Q2 		$216M Sell
12,565,308
-176,963
-1% -$2.91M 0.11% 222
2020
Q1 		$150M Buy
12,742,271
+380,860
+3% +$7.16M 0.1% 229
2019
Q4 		$290M Buy
12,361,411
+2,026,380
+20% +$44.8M 0.15% 170
2019
Q3 		$191M Buy
10,335,031
+1,009,504
+11% +$18.6M 0.1% 240
2019
Q2 		$173M Buy
9,325,527
+746,650
+9% +$14.9M 0.09% 256
2019
Q1 		$210M Buy
8,578,877
+157,586
+2% +$4.13M 0.11% 224
2018
Q4 		$218M Buy
8,421,291
+2,563,015
+44% +$70.5M 0.13% 202
2018
Q3 		$185M Sell
5,858,276
-88,723
-1% -$3.3M 0.09% 245
2018
Q2 		$231M Sell
5,946,999
-1,095,894
-16% -$34.9M 0.12% 210
2018
Q1 		$194M Sell
7,042,893
-1,152,810
-14% -$26.2M 0.1% 227
2017
Q4 		$148M Sell
8,195,703
-227,474
-3% -$3.71M 0.07% 285
2017
Q3 		$136M Buy
8,423,177
+45,588
+0.5% +$715K 0.07% 291
2017
Q2 		$116M Sell
8,377,589
-75,506
-0.9% -$1.09M 0.06% 319
2017
Q1 		$127M Buy
8,453,095
+767,527
+10% +$10.6M 0.06% 308
2016
Q4 		$101M Sell
7,685,568
-50,280
-0.6% -$789K 0.05% 344
2016
Q3 		$133M Sell
7,735,848
-16,612
-0.2% -$308K 0.07% 283
2016
Q2 		$140M Buy
7,752,460
+229,182
+3% +$4.47M 0.08% 281
2016
Q1 		$143M Buy
7,523,278
+1,653,008
+28% +$32.6M 0.08% 272
2015
Q4 		$157M Buy
5,870,270
+35,130
+0.6% +$939K 0.08% 254
2015
Q3 		$142M Sell
5,835,140
-522,154
-8% -$17.4M 0.07% 280
2015
Q2 		$198M Buy
6,357,294
+1,351,616
+27% +$25.4M 0.09% 247
2015
Q1 		$72.8M Buy
5,005,678
+540,740
+12% +$6.1M 0.03% 485
2014
Q4 		$44.9M Buy
4,464,938
+241,786
+6% +$1.97M 0.02% 627
2014
Q3 		$35.2M Buy
4,223,152
+542,571
+15% +$5.05M 0.02% 705
2014
Q2 		$45.3M Buy
3,680,581
+429,228
+13% +$5.13M 0.02% 631
2014
Q1 		$45.2M Buy
+3,251,353
New +$43.4M 0.02% 614

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Franklin Resources's HRTX Position: Q2 2025 in Review

Franklin Resources sold out of Heron Therapeutics (HRTX) in Q2 2025, closing a stake of 77,552 shares — an estimated $171K sold.

Franklin Resources first reported a position in HRTX in Q1 2014 and held it in 45 quarters. The position peaked at $290M in Q4 2019. 171 funds tracked by Wall St. Rank hold HRTX as of Q2 2025.

  • Franklin Resources reported no remaining Heron Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Franklin Resources sold 77,552 Heron Therapeutics shares in Q2 2025, an estimated $171K.
  • Franklin Resources first reported a position in Heron Therapeutics in Q1 2014 and held it in 45 quarters.
  • Franklin Resources's Heron Therapeutics position peaked at $290M in Q4 2019.
  • 171 funds tracked by Wall St. Rank held Heron Therapeutics as of Q2 2025.

Based on Franklin Resources's 13F filing for Q2 2025, filed 12 Aug 2025.